Beta Bionics | 8-K: Current report
This article is an 8-K current report filing for Beta Bionics. The content is simply "Document", indicating that the full report details would be contained within an attached document. An 8-K filing is used by companies to announce significant events that investors should know about.
Beta Bionics says Mint commercialization expected by end-Q2 2027, subject to FDA clearance
Beta Bionics (BBNX) anticipates full commercialization of its Mint product by the end of the second quarter of 2027, contingent on FDA clearance. This timeline is based on the FDA's initial responses to the Mint ACE insulin pump 510(k) submission. The company is also scaling manufacturing to meet projected launch demand, with planned features including a 200-unit reservoir, 3-day wear, smartphone control, and CGM compatibility.
No-recharge insulin patch pump targets 2027 launch pending FDA clearance
Beta Bionics (BBNX) announced it expects to fully commercialize its Mint insulin patch pump by the end of Q2 2027, pending FDA 510(k) clearance. The company has made progress in scaling manufacturing to meet anticipated demand. Key features of the Mint pump include compatibility with Beta Bionics' iAGC algorithm, leading CGMs, smartphone control, three-day wear, and a 200-unit reservoir, with a design intended to limit environmental waste.
Beta Bionics Expects Commercialization of Mint Insulin Patch Pump in 2027
Beta Bionics is targeting the commercial launch of its novel insulin patch pump, the Mint, in 2027. The device aims to provide a more discreet and simplified insulin delivery solution for people with diabetes, potentially improving treatment adherence and quality of life. This development follows the recent FDA clearance of their iLet Bionic Pancreas system, signaling Beta Bionics' continued innovation in automated insulin delivery.
[144] Beta Bionics, Inc. SEC Filing
This article reports on a Form 144 SEC filing by Beta Bionics, Inc. (BBNX). The filing, dated May 21, 2026, concerns the proposed sale of 1998 shares of common stock, acquired via Restricted Stock Units, with an aggregate market value of $20,199.78. The sale is to be handled by Morgan Stanley Smith Barney LLC on NASDAQ.
Mint patch pump launch target set for Q2 2027 by Beta Bionics (NASDAQ: BBNX)
Beta Bionics (NASDAQ: BBNX) has announced that it targets the full commercialization of Mint, its patch insulin pump, by the end of Q2 2027, subject to FDA regulatory clearance. The updated timeline is based on initial FDA responses and progress in scaling manufacturing, anticipating capacity to meet launch demand. Mint is designed to offer a 200-unit insulin reservoir, three days of wear, smartphone control, and compatibility with leading continuous glucose monitors and Beta Bionics’ adaptive dosing algorithm.
Beta Bionics Updates Commercialization Timeline Expectations for Mint™, its Patch Pump in Development
Beta Bionics announced an updated commercialization timeline for its Mint™ patch pump, expecting full commercialization by the end of Q2 2027, pending FDA regulatory clearance. The timeline is based on initial FDA responses and progress in manufacturing scaling. Mint is designed to be compatible with Beta Bionics’ adaptive insulin dosing algorithm, offering innovative features for people with diabetes.
Beta Bionics Price Target Cut to $11.00/Share From $23.00 by B of A Securities
B of A Securities has revised its price target for Beta Bionics, cutting it significantly from $23.00 to $11.00 per share. This adjustment reflects a more cautious outlook on the company's future performance or market conditions impacting its valuation.
Beta Bionics, Inc. Stock 12‑Month Price Target Cut to $19.18, Implies 103% Upside
Beta Bionics, Inc. (BBNX) has seen its average 12-month price target cut by analysts from $20.27 to $19.18, with forecasts ranging from $11 to $32 per share. This new target still implies a substantial 103% potential upside based on the May 15 closing price. The consensus analyst rating remains a "Buy" from 11 analysts.
BofA Adjusts Price Target on Beta Bionics to $11 From $23
BofA has reportedly adjusted its price target for Beta Bionics (BBNX) shares, lowering it to $11 from the previous $23. The article also briefly mentions Unity Software's (U.US) Q4 earnings, noting a 35% year-over-year revenue increase to $609 million, although the company reported a quarterly loss of 66 cents per share.
BBNX Forecast — Price Target — Prediction for 2027
This article provides a price target and forecast for Beta Bionics, Inc. (BBNX) for 2027, based on analysis from 11 analysts. The consensus price target is $20.27, with a "buy" rating, despite an expected negative EPS for the next quarter. The company's revenue for the next quarter is projected to reach $31.50 million USD.
Eventide (BBNX) reports 5.95M shares — 13.4% stake in Beta Bionics
Eventide Asset Management, LLC disclosed a 13.4% beneficial ownership stake in Beta Bionics (BBNX), totaling 5,945,488 shares as of March 31, 2026. This holding is split across the Eventide Gilead Fund, Eventide Healthcare & Life Sciences Fund, and separately managed accounts. The filing, a Schedule 13G/A, indicates a passive investment intent, explicitly disclaiming control in accordance with Rule 13d-4.
RTW Investments reports 2.0M-share stake in Beta Bionics (NASDAQ: BBNX)
RTW Investments and Roderick Wong have reported a 2,000,000-share position in Beta Bionics, Inc. (NASDAQ: BBNX), representing a 4.5% stake. This information comes from an amended passive investment disclosure (Schedule 13G/A). The shares are held on behalf of the RTW Funds, with shared voting and dispositive power attributed to RTW Investments and Dr. Roderick Wong.
Beta Bionics | SCHEDULE 13G/A: Others
This article consists solely of the title "Beta Bionics | SCHEDULE 13G/A: Others" and the content "Document". It indicates the filing of a Schedule 13G/A by an entity related to Beta Bionics. The filing is likely an amendment to a previous statement of beneficial ownership.
Farallon and Zone Holdings disclose ownership in Beta Bionics (BBNX) — 13G/A
Farallon-related entities and Zone Healthcare Holdings, LLC have filed an amended passive investment disclosure (13G/A) for Beta Bionics (BBNX). Zone Healthcare Holdings, LLC reported owning 2,560,220 shares (5.8%), while several Farallon funds and individual reporting persons hold varying stakes, with some individuals reporting 3,607,920 shares each (8.1%). The filing specifies ownership, voting, and dispositive powers for the reported shares.
Number of shareholders of Beta Bionics, Inc. – NASDAQ:BBNX
The article focuses on the number of shareholders for Beta Bionics, Inc. (NASDAQ: BBNX). It presents a placeholder for shareholder data across different periods, noting changes and percentage changes. The content appears to be a financial data page from TradingView, including various navigation and informational links.
Beta Bionics | SCHEDULE 13G/A: Others
This article is a SCHEDULE 13G/A filing related to Beta Bionics. A Schedule 13G/A is an amendment to a Schedule 13G, which is an SEC filing indicating beneficial ownership of more than 5% of a class of a company's stock by an institutional investor. The "Others" designation suggests the filing is not made by one of the more common types of beneficial owners like an investment adviser or bank, but rather another entity.
[SCHEDULE 13G/A] Beta Bionics, Inc. Amended Passive Investment Disclosure
This SEC filing (Schedule 13G/A) for Beta Bionics, Inc. (BBNX) details an amended passive investment disclosure by multiple entities under the Soleus Capital umbrella, including Soleus Private Equity Fund II, L.P., and Soleus Capital Master Fund, L.P. The filing outlines their beneficial ownership, shared voting and dispositive power, and the percentage of the class of stock they represent. Guy Levy is identified as a key managing member across these entities and holds the largest aggregate beneficial ownership.
Beta Bionics (BBNX) price target decreased by 11.15% to 20.99
The article reports that the price target for Beta Bionics (BBNX) has been decreased by 11.15%, setting the new target at $20.99. No further details regarding the reasons for this change or the analyst responsible are provided.
Beta Bionics, Inc. (BBNX) reports Q1 loss, misses revenue estimates
Beta Bionics, Inc. (BBNX) reported a Q1 loss, failing to meet revenue estimates. This suggests the company's financial performance in the first quarter fell short of expectations, indicating potential challenges or slower-than-anticipated growth despite its innovative diabetes management technology. The news may impact investor sentiment regarding the company's near-term outlook.
Beta Bionics, Inc. (BBNX) reports Q1 loss, misses revenue estimates
Beta Bionics, Inc. (BBNX) reported a Q1 loss of $0.66 per share, which was wider than the analyst estimate of a $0.57 loss per share. The company also missed revenue expectations, posting $5.99 million against an anticipated $6.87 million. Over the last 90 days, EPS estimates for BBNX have seen a mixed revision trend, with two upward adjustments and six downward adjustments.
BBNX.O Stock News Today | Earnings, Events & Price Alerts
This article provides recent news and event information for BBNX.O (Beta Bionics), including its latest financial results, earnings highlights, and share performance. Key updates include Q1 2026 financial results, which beat expectations, and a raised gross margin forecast for FY26. The article also touches on broader market movements, such as U.S. indices retreating and the energy sector gaining.
Beta Bionics, Inc. (NASDAQ:BBNX) Given Average Rating of "Moderate Buy" by Analysts
Beta Bionics, Inc. (NASDAQ:BBNX) has received an average rating of "Moderate Buy" from twelve analysts, with an average one-year price target of $22.00. Despite beating Q1 EPS estimates, the company faces high volatility and a negative net margin. Institutional investors have recently adjusted their positions in the stock.
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Beta Bionics, Inc. (BBNX) and Danaher (DHR)
Analysts have issued mixed ratings for healthcare stocks Beta Bionics, Inc. (BBNX) and Danaher (DHR). TD Cowen analyst Mathew Blackman maintained a Hold rating on Beta Bionics with a $16.00 price target, while TD Cowen analyst Daniel Brennan assigned a Buy rating to Danaher with a $240.00 price target, noting a "Strong Buy" consensus for Danaher.
Surging Q1 sales lead Beta Bionics (NASDAQ: BBNX) to lift 2026 guidance
Beta Bionics (NASDAQ: BBNX) announced strong first-quarter 2026 results, with net sales increasing 57% to $27.6 million and gross margin improving to 59.5%. The company subsequently raised its full-year 2026 revenue guidance to $131–$136 million and increased its gross margin outlook. This positive performance was primarily driven by significant growth in the Pharmacy Benefit Plan channel, alongside solid liquidity with $239.5 million in cash and investments.
Beta Bionics (BBNX) grows iLet sales to $27.6M while narrowing quarterly loss
Beta Bionics reported significant revenue growth for Q1 2026, with net sales reaching $27.6 million, up from $17.6 million in the prior year, primarily driven by increased adoption of its iLet insulin delivery system. Despite continued heavy investment in research and development and sales and marketing, the company narrowed its net loss to $21.9 million from $28.7 million in the same period last year. Beta Bionics maintains a strong liquidity position with $239.5 million in cash and investments, supporting ongoing commercialization and pipeline expansion including a patch pump and a bihormonal iLet system.
Beta Bionics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:BBNX) 2026-04-21
Beta Bionics, Inc. (BBNX) published its Q1 2026 earnings call presentation, reporting an EPS of -$0.36, beating estimates by $0.10, and revenue of $27.63 million, exceeding expectations by $658.40K with a 56.62% year-over-year increase. This slide deck accompanies their earnings call from April 21, 2026.
Beta Bionics Raises 2026 Outlook on Strong Sales Amid Patient Growth Dip
Beta Bionics (Nasdaq: BBNX) reported a 57% year-over-year revenue increase in Q1 2026, reaching $27.6 million, largely driven by its strategic shift to the Pharmacy Benefit Plan (PBP) channel. This strong performance led the company to raise its full-year 2026 revenue and gross margin guidance, despite a sequential dip in new patient starts attributed to industry seasonality. The company's focus on expanding market access and its innovation pipeline, including a new bihormonal system, position it for continued growth in the competitive diabetes technology landscape.
Beta Bionics Q1 2026: Revenue $27.6M, EPS (0.49) — 10-Q Summary
Beta Bionics (BBNX) reported Q1 2026 net sales of $27.6 million, a 57% increase year-over-year, driven by higher single-use product sales and new patient starts. Despite a widened operating loss of $(24.3) million, the net loss narrowed to $(21.9) million, or $(0.49) per share. The company saw improved gross margins of 59.5% due to production scale and cost absorption, and continued progress in product development and regulatory efforts for its iLet program.
Diabetes tech maker Beta Bionics lifts outlook after 57% sales jump
Beta Bionics (NASDAQ: BBNX) announced strong Q1 2026 financial results, with net sales jumping 57% year-over-year to $27.6 million, driven by significant growth in its Pharmacy Benefit Plan (PBP) channel. The company also raised its full-year 2026 revenue guidance to $131M–$136M and improved gross margin estimates, despite experiencing a sequential decline in new patient starts and continued operating losses. Beta Bionics maintained a healthy cash balance and continues to advance its diabetes management solutions, including the iLet Bionic Pancreas.
Beta Bionics, Inc. (BBNX) soars 10.3%: Is further upside left in the stock?
Beta Bionics, Inc. (BBNX) experienced a 10.3% surge in its stock price, outperforming the S&P 500's daily gain. This significant movement prompts an analysis into whether the stock has further potential for growth. Investors are keen to understand the factors driving this increase and assess future prospects for BBNX.
Beta Bionics (NASDAQ:BBNX) Trading Down 4.9% Following Analyst Downgrade
Beta Bionics (NASDAQ:BBNX) shares dropped 4.9% after Truist Financial lowered its price target from $25 to $18, influencing several other firms to also trim their targets. Despite a mixed analyst consensus of "Moderate Buy" and an average target of $22, the company remains unprofitable with a market cap near $556M and a negative P/E of -6.34. The company recently reported Q4 EPS of -$0.30, beating estimates.
Earnings Preview: Beta Bionics to Report Financial Results Post-market on April 21
Beta Bionics (BBNX.US) is scheduled to release its financial results after the market closes on April 21 ET. Analysts estimate the company to report revenue of USD26.97 million for 2026 Q1, marking a 52.87% year-over-year increase, with an estimated EPS of USD-0.503, indicating a 45.95% narrowing of net loss year-over-year. The report uses US-GAAP accounting standards.
Truist Financial Maintains Beta Bionics(BBNX.US) With Buy Rating, Cuts Target Price to $18
Truist Financial has reiterated its Buy rating on Beta Bionics (BBNX.US) but has lowered the target price for the stock to $18. This adjustment reflects a revised outlook from the financial firm on the company's future performance or market conditions.
Beta Bionics (NASDAQ:BBNX) Trading Up 8.3% - What's Next?
Beta Bionics (NASDAQ:BBNX) saw an 8.3% stock jump, though trading volume was significantly lower than average. Analysts hold a "Moderate Buy" consensus rating with a $22.70 price target despite recent downgrades from Bank of America and Goldman Sachs. The company beat EPS expectations but remains unprofitable, has a modest market cap and high volatility, while institutional investors like Vanguard have increased their positions.
BBNX Options Chain — NASDAQ:BBNX
This page provides an options chain for Beta Bionics, Inc. (BBNX) on NASDAQ, offering data on call and put options. Users can monitor live pricing, Greeks, and implied volatility to build trading strategies. The platform also offers tools for tracking market movements and evaluating risks associated with options contracts.
Beta Bionics, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm has announced an investigation into Beta Bionics, Inc. (NASDAQ: BBNX) for possible securities fraud following a significant drop in its stock price. The investigation stems from a disclosure of preliminary Q4 2026 financial results, which revealed a substantial slowdown in new user acquisition, causing investor confidence to erode and the stock to plummet by 37.03%. The firm is encouraging affected investors to contact them for a complimentary case evaluation.
Beta Bionics, Inc. Investigated by the Portnoy Law Firm
The Portnoy Law Firm is investigating Beta Bionics, Inc. (NASDAQ: BBNX) for potential securities fraud after its stock price dropped 37.03% following preliminary Q4 2026 financial results. The decline was attributed to a significant slowdown in new user acquisition, with new patient starts growing 36% year-over-year compared to 68% in the previous quarter, causing a loss of investor confidence. The firm invites investors to contact them to discuss their legal rights.
BBNX Options Chain — NASDAQ:BBNX
This page provides access to the options chain for Beta Bionics, Inc. (BBNX) on the Nasdaq Stock Market. Users can monitor live pricing, Greeks, and implied volatility to track market movements and evaluate risks for available call and put options.
Companies Like Beta Bionics (NASDAQ:BBNX) Are In A Position To Invest In Growth
Beta Bionics (NASDAQ:BBNX) shows a promising financial position for growth despite being an unprofitable business. The company has a significant cash runway of 3.9 years, holding US$219 million in cash as of December 2025 against a cash burn of US$56 million last year. While its cash burn increased by 8.8% year-on-year, revenue grew by 54%, suggesting effective growth alongside spending.
Companies Like Beta Bionics (NASDAQ:BBNX) Are In A Position To Invest In Growth
Beta Bionics (NASDAQ:BBNX) has a strong cash runway of 3.9 years, with US$219m in cash and no debt as of December 2025. Although its cash burn increased by 8.8% year-on-year, revenue grew significantly by 54%, suggesting a healthy growth trajectory. The company's ability to raise additional capital without substantial dilution further strengthens its position for future growth investments.
[ARS] Beta Bionics, Inc. SEC Filing
This article announces an ARS SEC filing by Beta Bionics, Inc. (BBNX). The filing, dated April 10, 2026, is an ARS Form and is available as a PDF document. The article also provides an overview of Beta Bionics, including its stock data, market cap, and recent news and SEC filings.
BBNX Stock Price, Quote & Chart | BETA BIONICS INC (NASDAQ:BBNX)
BETA BIONICS INC (NASDAQ:BBNX) stock is currently priced at $10.63, showing a 19.98% increase today. The company, which specializes in medical devices like the iLet Bionic Pancreas, has a market cap of $471.759M and a ChartMill technical rating of 1/10 and fundamental rating of 4/10. Analysts anticipate a 124.69% price increase over the next year compared to the current price.
Executive pay and board elections at Beta Bionics (NASDAQ: BBNX) 2026 meeting
Beta Bionics (NASDAQ: BBNX) has announced its 2026 virtual annual meeting of stockholders on May 21, 2026, where shareholders will vote on the election of two Class I directors (Sean Carney and Christy Jones) and the ratification of Ernst & Young LLP as the independent registered public accounting firm. The proxy statement also details executive compensation for 2025, with CEO Sean Saint receiving over $12 million, and outlines the company's corporate governance policies, including risk oversight and director independence.
Artificial Pancreas System Market to Hit US$ 2,070.82 Million
The global artificial pancreas system market, valued at US$ 456.97 million in 2024, is projected to reach US$ 2,070.82 million by 2033, demonstrating an 18.0% CAGR during the forecast period from 2025-2033. This growth is driven by the increasing prevalence of diabetes, technological advancements in continuous glucose monitoring and insulin delivery systems, and rising awareness of wearable medical devices. Key players such as Medtronic Plc, Tandem Diabetes Care, Inc., and Beta Bionics are actively developing and enhancing these systems to improve glucose control and patient convenience.
Beta Bionics 2-Year Revenue Jumps 736% to $103.2 Million
Beta Bionics saw its revenue soar 736% over two years, reaching $103.2 million, driven by the demand for its iLet Bionic Pancreas. The company, which recently went public, is expanding its sales force and developing new products like the Mint patch pump and a bihormonal iLet system. Despite a recent stock dip, Beta Bionics is focused on making its advanced diabetes management technology more accessible through pharmacy reimbursement and continuous innovation.
JPMorgan Chase Boosts Stake in Beta Bionics
JPMorgan Chase has significantly increased its investment in Beta Bionics, a medical device company developing automated insulin delivery solutions for type 1 diabetes. This substantial boost in stake, over 3,200%, indicates growing confidence from Wall Street in Beta Bionics' potential to revolutionize diabetes care with its bionic pancreas technology. The investment firm now holds approximately 0.47% ownership in the Boston-based company.
Segmentation, Major Trends, and Competitive Dynamics in the Insulin Patch Pumps Market
The global insulin patch pumps market is projected to reach $2.55 billion by 2030, growing at a CAGR of 10.2%, driven by advancements in diabetes care technology and increased adoption of closed-loop systems. Key players like Insulet Corporation and Medtronic PLC are innovating with products like the Embecta insulin patch pump, which recently received FDA clearance. The market is segmented by type (reusable, disposable, smart, automated), mode (basal, bolus), and application (Type 1 and Type 2 diabetes), reflecting diverse patient needs and technological progress.
New diabetes report tool flags missed meals, insulin pauses
Beta Bionics has introduced "Bionic Insights" within its Bionic Reports, a new feature designed to help clinicians optimize diabetes care for users of the iLet Bionic Pancreas. This tool organizes patient data into "Areas of Success" and "Areas of Opportunity," highlighting issues like missed meals, insulin pauses, and prolonged hyperglycemia. The aim is to provide actionable guidance, reduce time spent on data interpretation, and facilitate more focused conversations between healthcare providers and patients to improve glucose control.
Beta Bionics Receives 'Moderate Buy' Consensus from Analysts
Beta Bionics (NASDAQ: BBNX), a medical device company specializing in automated insulin delivery, has received a 'Moderate Buy' consensus rating from eleven analysts. The average 12-month price target is $23.20. While the company's iLet Bionic Pancreas system shows promise, analysts' views are mixed due to competitive landscape and regulatory hurdles.
